Altaris to Acquire AI Drug-Development Firm Simulations Plus for ~$375M — 26% Premium, Combination With Chemical Computing Group Planned

Healthcare investment firm Altaris agreed to acquire Simulations Plus (Nasdaq: SLP), a provider of AI-accelerated drug-development simulation software, for approximately $375 million in an all-cash deal at $18.50 per share — a 26% premium to the 60-day volume-weighted average price. Altaris plans to combine Simulations Plus with its existing portfolio company Chemical Computing Group, which provides molecular design software to pharmaceutical and materials companies, creating an integrated computational drug-discovery platform. The transaction requires stockholder and regulatory approval and is expected to close in Q4 2026.